383 related articles for article (PubMed ID: 32605254)
1. DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Tomasova K; Cumova A; Seborova K; Horak J; Koucka K; Vodickova L; Vaclavikova R; Vodicka P
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32605254
[TBL] [Abstract][Full Text] [Related]
2. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
4. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Kristeleit RS; Miller RE; Kohn EC
Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
[TBL] [Abstract][Full Text] [Related]
5. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
6. Exploiting DNA repair defects in colorectal cancer.
Reilly NM; Novara L; Di Nicolantonio F; Bardelli A
Mol Oncol; 2019 Apr; 13(4):681-700. PubMed ID: 30714316
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
9. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
10. Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Somyajit K; Mishra A; Jameei A; Nagaraju G
Carcinogenesis; 2015 Jan; 36(1):13-24. PubMed ID: 25292178
[TBL] [Abstract][Full Text] [Related]
11. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
12. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
13. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
Milanesio MC; Giordano S; Valabrega G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
[TBL] [Abstract][Full Text] [Related]
15. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
Chartron E; Theillet C; Guiu S; Jacot W
Crit Rev Oncol Hematol; 2019 Jan; 133():58-73. PubMed ID: 30661659
[TBL] [Abstract][Full Text] [Related]
16. Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Liu X; Yang H; Wu X; Huang K; Ma P; Jiang P; Zheng W; Tang T; Liu D
Oncol Lett; 2019 Sep; 18(3):2789-2798. PubMed ID: 31452757
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
20. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]